David Sidransky
Lead Independent DirectorDr. David Sidransky, M.D., Ph.D. is Director of Nectin Therapeutics Ltd. He was Independent Director of Orgenesis Inc. from July 18, 2013 to June 27, 2024. Dr. Sidransky is Chairman of Ayala Pharmaceuticals, Inc., since October 19, 2023. He was a Chief Clinical & Medical Advisory to the CEO at Secura Bio, Inc. until July 2025. Dr. Sidransky sits on the National Board of Scientific Advisors of the National Cancer Institute. He is also Chairman of the Medical Advisory Board of the Flight Attendants Medical Research Foundation and the Adenocystic Carcinoma Research. Dr. Sidransky served as an Independent Director at Cactus Acquisition Corp. 1 Limited until April 11, 2024. He serves as Independent Non-Executive Director at Ascentage Pharma Group International since March 31, 2021 and serves as Lead Independent Non-Executive Director since December 30, 2025. He served as Member of Advisory Board at Flagship Biosciences, Inc. He serves as a Co-Founder, General Partner at Israel Biotech Fund. Dr. Sidransky is the Chairman or director of several biotechnology companies of the Israel Biotech Fund. Dr. Sidransky is a Member of Advisory Board at Medial EarlySign Ltd. He served as Director at Biond Biologics Ltd. since 2017 until May 2021. Dr. Sidransky has served as Vice Chairman of the board of directors and was, until the merger with Eli Lilly, a director of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Dr. Sidransky is the Owner of Biomerk, Inc. and serves as its Executive Officer. Dr. Sidransky has been a Director for the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore Maryland since 1994. Dr. Sidransky is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky has experience in the practice and instruction of medicine with expertise in oncology and molecular pathology, as well as in providing scientific guidance to institutions and corporations. Dr. Sidransky served as Advisor of Agennix Incorporated. He is serving and has served on scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC. Dr. Sidransky serves as Independent Chairman of the Board of Directors at Ayala Pharmaceuticals Inc. since November 2017. Dr. Sidransky serves as the Chairman of the Early Detection Research Network. He served as Member of Scientific Advisory Board at C2i Genomics, Inc until March, 2023. He serves as the Chairman of Tamir Biotechnology, Inc. Dr. Sidransky serves as the Chairman of Scientific Advisory Board at Tamir Biotechnology, Inc. and Cangen Biotechnologies, Inc. Dr. Sidransky serves as the Chairman at Advaxis, Inc. since May 27, 2015. Dr. Sidransky serves as a Director of Efranat Ltd. Dr. Sidransky is a Director of Eocene Ltd. (formerly known as Galmed Pharmaceuticals Ltd.) from June 2014 and has been its Lead Independent Director since December 26, 2018 and served as its External Director since June 2014. Dr. Sidransky has been Independent Director of Orgenesis Inc. since July 18, 2013. Dr. Sidransky has been an External Director of Morria Biopharmaceuticals Plc since September 25, 2007 and Tamir Biotechnology, Inc. since June 2, 2004. He has been an Independent Director of Champions Oncology, Inc. since August 14, 2007 and was its Lead Director since November 2016 until August 25, 2025. Dr. Sidransky serves as Member of Scientific Board at BCD Innovations, Inc. Dr. Sidransky serves as a Member of Scientific Advisory Board at Targeted Molecular Diagnostics, LLC. Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics and Pathology at Johns Hopkins University School of Medicine. Dr. Sidransky serves as a Member of Advisory Board of Gene Express Inc. Dr. Sidransky has been an Independent Director of Advaxis, Inc. since July 16, 2013. Dr. Sidransky served as a Director of Celsus Therapeutics Plc since June 2007. He serves as a Member of Colorectal Cancer Clinical Advisory Board of StageZero Life Sciences Ltd. (formerly known as GeneNews Limited). Dr. Sidransky serves on the Board of Directors of Xenomics. He has been Member of Scientific Board of Optimata Ltd. since August 14, 2006. Dr. Sidransky served as Chairperson of the first (September 2006) and is the chairperson of the second (September 2007) AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development. He served as the Chairman of Medical Advisory Board at Zila, Inc. Dr. Sidransky served as the Chairman of Champions Oncology, Inc. from October 2007 to November 2016. Dr. Sidransky served as the Vice Chairman of Immune Pharmaceuticals, Inc. from August 2013 to January 14, 2015 and also served as its Lead Director. Dr. Sidransky served as Vice Chairman of Tamir Biotechnology, Inc. since January 2007. Dr. Sidransky has served as Vice Chairman of ImClone Systems LLC since June 15, 2006. Dr. Sidransky served as a Member of Medical Advisory Board at Rosetta Genomics, Ltd. Dr. Sidransky has been with early detection of cancer since 1994. Dr. Sidransky served as a Director of Rosetta Genomics, Ltd. since December 22, 2009 until November 13, 2017. Dr. Sidransky served as a Member of Scientific Advisory Board at Aureon Laboratories, Inc. (formerly Aureon Biosciences Corporation). Dr. Sidransky served as Director of TrovaGene, Inc. from August 2006 to November 19, 2008 and Immune Pharmaceuticals, Inc. from August 25, 2013 to January 14, 2015. Dr. Sidransky served as a Member of the Scientific Advisory Board at OncoMethylome Sciences (a/k/a MDxHealth SA). Dr. Sidransky served as a Member of Scientific Advisory Board of Gammacan International Inc., since April 28, 2005. Dr. Sidransky served as Director of Zila, Inc. from October 24, 2006 to August 1, 2007 and Lumara Health, Inc. from June 2010 to September 2013. Dr. Sidransky served as Lead Independent Director of Tamir Biotechnology, Inc. since January 2007. Dr. Sidransky served as a Director of Akari Therapeutics, Plc until September 18, 2015. Dr. Sidransky served as a Director of the American Association of Cancer Research, the American Association for the Advancement of Science and the New York Academy of Sciences from 2005 to 2008. Dr. Sidransky served as a Lead Director of ImClone Systems LLC since January 26, 2004 and its Director from January 26, 2004 to November 21, 2008. Dr. Sidransky served on the Board of Scientific Counselors at the National Association of Dental and Craniofacial Research. Dr. Sidransky serves as a Member of numerous National Institutes of Health Working Groups,
公司職務
- 公司名稱Eocene Ltd.股票代碼EOCN職務Lead Independent Director共事同僚
- ABAllen BaharaffCo-Founder, President, CEO & Chairman
- DCDoron CohenChief Financial Officer
- GNGuy NehemyaCOO & Data Protection Officer
- YSYohai StenzlerChief Accounting Officer
- LHLiat HayardenyChief Scientific Officer
- DSDavid SidranskyLead Independent Director
- APAmir PoshinskiIndependent Director
- SNShmuel NirIndependent Director
- VRVlad RatziuMember of Scientific Advisory Board
- 公司名稱Champions Oncology, Inc.股票代碼CSBR職務Independent Director共事同僚
